Some cardiovascular therapeutics inhibit paraoxonase 1 (PON1) from human serum

Area of Science:

• Biochemistry
• Pharmacology
• Toxicology

Background:

• Atherosclerosis accounts for 50% of mortality in Western societies.
• Organophosphates pose a significant risk and terrorist threat.
• Paraoxonase enzyme (PON) acts as a bioscavenger against both atherosclerosis and organophosphate toxicity, making PON studies scientifically important.

Purpose of the Study:

• To purify PON1 enzyme from human serum.
• To investigate the inhibitory effects of specific cardiovascular drugs on human serum PON1 activity.
• To determine the inhibition kinetics (IC50 and Ki values) of these drugs.

Main Methods:

• Simple three-step purification of PON1 from human serum: ammonium sulfate precipitation, ion-exchange chromatography, and gel filtration chromatography.
• Enzyme activity assays to determine IC50 and Ki values.
• Kinetic analysis of drug inhibition (competitive, uncompetitive, noncompetitive).

Main Results:

• PON1 was successfully purified from human serum.
• Cardiovascular drugs including digoxin, metoprolol tartrate, verapamil, diltiazem, amiodarone, dobutamine, and methylprednisolone exhibited inhibitory effects on PON1 activity.
• Digoxin demonstrated the highest inhibition rate (lowest IC50 and Ki values).
• Inhibitory mechanisms varied: methylprednisolone and amiodarone were competitive inhibitors, verapamil and dobutamine were uncompetitive inhibitors, and others acted as noncompetitive inhibitors.

Conclusions:

• Human serum PON1 can be effectively purified using a straightforward three-step method.
• Several commonly used cardiovascular drugs interact with and inhibit PON1 enzyme activity.
• Understanding these drug-enzyme interactions is crucial for assessing potential therapeutic implications and risks.